Recent research suggests that Ozempic and similar GLP-1 drugs may lower the risk of dementia in those with type 2 diabetes. Discover how these drugs are being tested for dementia prevention!
Eli Lilly is set to unveil results from trials of orforglipron, its groundbreaking once-daily obesity pill, potentially revolutionizing weight loss treatment by offering a needle-free alternative. Analysts predict it could capture a significant share of the $150 billion GLP-1 market.
A groundbreaking study reveals that a biologic drug may delay Alzheimer's symptoms in individuals with genetic predispositions. With promising results, researchers emphasize the importance of continued funding for further investigation.
In a significant ruling, a U.S. judge has halted the Trump administration's proposed cuts to federal research funding, which threatened layoffs and lab closures across the nation. This decision is a major win for institutions reliant on federal grants.
In a significant victory for medical research, a federal judge has temporarily blocked the Trump administration's proposed cuts to NIH funding that could jeopardize patient care and cost thousands of jobs. The ruling comes after multiple lawsuits from states and research institutions.
A groundbreaking study from Washington University reveals that new Alzheimer’s medications could extend patient independence by up to 13 months. Discover how these findings reshape treatment decisions.
Groundbreaking personalized mRNA vaccine demonstrates potential in reducing the recurrence of pancreatic cancer post-surgery by training immune cells to fight the disease. Learn how this innovative approach may revolutionize cancer treatment.
